Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 12/20 | 0.42 |
| ▸ | TP53 | P04637 | 7/20 | 0.42 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26977721 | 0.86 | CA2 (0.42) | CA2MAPTTP53THRBUSP2 | |
| SCHEMBL2176037 | 0.81 | CA2 (0.54) | CA2MAPTTP53CYP2A6LMNA | |
| SCHEMBL2089910 | 0.79 | MTNR1A (0.45) | CA2MAPTPOLB | |
| SCHEMBL288542 | 0.74 | CA1 (0.47) | CA2MAPTCYP2A6 | |
| SCHEMBL29469856 | 0.74 | CA1 (0.47) | CA2MAPTCYP2A6 | |
| SCHEMBL28920141 | 0.74 | CA2 (0.49) | CA2MAPTLMNAPOLB | |
| SCHEMBL422138 | 0.72 | CYP2A6 (0.50) | CA2MAPTTP53THRBUSP2 | |
| SCHEMBL423281 | 0.71 | CYP2A6 (0.64) | CA2MAPTTP53THRBUSP2 | |
| SCHEMBL30729957 | 0.70 | PDPK1 (0.44) | CA2MAPTCYP2A6 | |
| SCHEMBL7213509 | 0.70 | PDPK1 (0.44) | CA2MAPTCYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973051-B2 | Aminothiazoles as FBPase inhibitors for diabetes | HOFFMAN-LA ROCHE INC. (US) | 2011-07-05 | — | — | US | disclosed |
| EP-2227468-A1 | AMINOTHIAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2010-09-15 | — | — | EP | disclosed |
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| WO-2009068467-A1 | AMINOTHIAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143448-A1 | NEW AMINOTHIAZOLES AS FBPASE INHIBITORS FOR DIABETES | FBP1, SLC5A1, DPP4 | CA2 1616/4885MAPT 1274/4885TP53 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.